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The global incidence of diabetes mellitus, 
specifically Type 2 diabetes, is increas-
ing at such an alarming rate that it has 
been cited by many as a global epidemic 
alongside and intertwined with the obes-
ity epidemic [1,2]. The disease is caused 
by defects in both insulin signaling and 
insulin secretion. The roles of the para-
sympathetic system and cholinergic input 
in the regulation of insulin secretion have 
long been established [3,4]. However, it is 
only recently, with the use of transgenic 
and knockout mice technology, that the 
M
3
-muscarinic receptor (M3R) has been 
identified as the bona fide acetylcholine 
receptor that is responsible for enhanc-
ing glucose-dependent insulin release in 
the b-cells of the islets of Langerhans in 
the pancreas [5]. The question is, does the 
determination of the role played by the 
M3R in insulin release provide a novel 
target for the treatment of diabetes?
The determination of the involvement 
of the M3R in insulin release has occurred 
alongside the discovery of the cellular sign-
aling cascades by which the M3R mediates 
glucose-induced insulin release. The out-
come of these studies has been the intriguing 
observation that the M3R appears able to 
regulate insulin secretion via a number of 
distinct signaling cascades. One of these 
involves the protein kinase PKD1, which is 
activated by the phosphory lated form of the 
M3R in a process that results in secretory 
vesicle priming [6]. This protein kinase is 
also negatively regulated by the mitogen-
activated protein kinase p38d – in this case, 
the M3R is proposed to stimulate insulin 
release by inhibiting p38d activity [7]. 
In another mechanism, the ability of 
the M3R to mediate insulin release via 
inositol 1,4,5-triphosphate (IP
3
)/calcium-
dependent signaling has been demonstrated 
to be modulated by the adaptor protein 
ankyrin-B. Here, ankyrin-B modulates 
M3R-mediated insulin release by binding 
to, and thus stabilizing, IP
3
 receptors in 
b-cells [8]. Pancreatic islets from hetero-
zygous ankyrin-B-mutant (ankB+/-) mice 
exhibited a reduction in both basal and 
carbachol-stimulated intracellular calcium 
release [8], suggesting that the IP
3
 receptor 
is stabilized in the open state.
The M3R has also been demonstrated 
to activate a sodium channel, designated 
the sodium leak channel nonselective 
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(NALCN) and formerly named Rb21, then 
VGCNL1. This channel belongs to the four-
domain ion channel family. Importantly, M3R 
activation of the NALCN channel in the 
model pancreatic b-cell line, MIN-6, does 
not occur via receptor signaling to the hetero-
trimeric G-protein-dependent pathway but, 
rather, occurs through a pathway dependent 
on a Src family of tyrosine kinases-dependent 
pathway [9]. In addition, the regulators of the 
G-protein signaling protein, RGS4, negatively 
modulate M3R-mediated insulin secretion in 
b-cells due to their selective inhibition of M3R 
signaling in b-cells [10]. 
These regulatory mechanisms appear to act 
in a co-ordinated fashion in vivo to mediate 
parasympathetic control of insulin release. The 
in vivo effects of muscarinic receptor agonists 
in regulating glucose-stimulated insulin secre-
tion were first examined over a decade ago [11]. 
Intravenous administration of carbachol-poten-
tiated glucose-stimulated insulin secretion in 
mice fed with either a control or a high-fat diet. 
Carbachol also normalized glucose-stimulated 
insulin secretion and glucose tolerance in mice 
subjected to a high-fat diet [11]. These data led 
to the proposal that the development of islet-
specific muscarinic agonists might be a feasible 
target to improve insulin secretion in Type 2 dia-
betes. However, it was not until recently that this 
proposal was vigorously investigated. Gautam 
and colleagues performed a series of studies, 
that concluded with the generation of transgenic 
mice that specifically expressed a constitutively 
active mutant of M3R in pancreatic b-cells, and, 
by doing so, mimicked the effects of a drug that 
chronically stimulated b-cell M3Rs [12]. These 
mutant mice exhibited markedly improved glu-
cose tolerance and increased serum insulin lev-
els, as well as resistance to diet-induced glucose 
intolerance and hyperglycemia [12]. These stud-
ies strongly support the hypothesis that chronic, 
continuous activation of b-cell M3Rs might pro-
duce beneficial effects on glucose homeostasis. 
These studies further established the therapeutic 
potential for M3R selective agonists for the treat-
ment of Type 2 diabetes. However, the use of 
such agonists may be limited by their possible 
side effects owing to other peripheral actions of 
M3Rs, such as smooth muscle contraction and 
saliva secretion. 
If targeting M3R receptors is to be success-
ful then ligands that are selective to the M3R 
subtype, and that do not also stimulate the 
other muscarinic receptor subtypes, namely 
M1, M2, M4 and M5, will have to be devel-
oped. The search for such ligands has been 
unsuccessful so far, largely owing to the fact 
that the acetylcholine binding sites on the 
muscarinic receptors are very similar between 
the five receptor subtypes. However, hope that 
pharmacologists can selectively target the mus-
carinic receptors has recently emerged, owing 
to the discovery of ligands that interact with 
allosteric sites on the receptors [13,14]. These 
so-called allosteric modulators target variant 
regions of the receptor and can therefore show 
subtype selectivity. It is anticipated that posi-
tive allosteric modulators, which increase the 
affinity and/or efficacy of acetylcholine to the 
M3R, could be used to enhance the effects of 
the natural ligand acetylcholine selectively at 
the M3R. 
In addition to allosteric modulators, the 
discovery that the M3R can potentiate insulin 
release through an arrestin-dependent mecha-
nism suggests that biased agonists that direct 
muscarinic receptor signaling via arrestins 
would be of therapeutic benefit [6]. The poten-
tial of biased agonists has been revealed for the 
b-adrenoceptor, where the therapeutic efficacy 
of carvedilol in the treatment of heart disease 
has been attributed to the fact that this lig-
and can direct signaling of the b-adrenoceptor 
via arrestin-dependent pathways [15]. Similar 
biased ligands that direct signaling of the 
M3R via arrestin signaling would be expected 
to potentiate insulin release from b-islets in 
a manner that results in reduced side effects, 
due to G-protein-dependent calcium signaling 
being minimized.
Alternatively, signaling proteins downstream 
of M3Rs in b-cells may be targeted. Carbachol 
augmentation of glucose-induced insulin secre-
tion was significantly impaired in islets prepared 
from ankB+/- mice or in rat islets following siRNA 
knockdown of ankyrin-B [8]. In addition, ankB+/- 
mice exhibited hyperglycemia after oral inges-
tion of glucose, and the R1788W mutation of 
ankyrin-B impaired its function in islets and is 
associated with Type 2 diabetes in Caucasians 
and Hispanics [8]. Although homozygous 
PKD1-knockout (PKD1-/-) mice are embry-
onically lethal [16], deletion of PKD1 in INS1 
insulinoma cells completely abolished the insu-
lin release induced by glucose and carbachol [7]. 
siRNA knockdown of PKD1 in mouse islets also 
impaired the M3R-mediated augmentation of 
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glucose-induced insulin secretion [6]. Although 
siRNA targeting of signaling pathways in islets 
is never going to be therapeutically feasible, these 
studies demonstrate that targeting the signaling 
pathways downstream of the M3R can effectively 
modulate insulin release.
Finally, NALCN may also appear to be a 
potentially attractive drug target for Type 2 
diabetes; since the NALCN current is too small 
to induce insulin release by itself but, instead, 
potentiates glucose-induced insulin secre-
tion [17], compounds that activate NALCN 
would be superior to the sulfonylureas, as such 
compounds would depolarize b-cells and stimu-
late insulin secretion only at normal and elevated 
blood glucose levels [9]. 
So much is now known about the M3R-
mediated insulin secretion pathway, yet so much 
more must still be done. Most, if not all, of the 
information gathered so far has been obtained 
from rodents. Although the physiological role 
of M3Rs in b-cells appears to be conserved 
between species, further studies are warranted 
to determine the effectiveness of b-cell M3Rs 
and/or downstream signaling components as 
drug targets for the treatment of Type 2 diabetes 
in humans.
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